Clinical trials: Healthy Volunteer, Type 2 Diabetes
Diabetes Mellitus, Type 2
A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of PF-05175157 in a dose-dependent fashion in healthy volunteers
- Trial name
- NCT01537497
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
- Trial name
- NCT03347968
- Testing
- MEDI0382, Warfarin, Esmolol
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Type 2 Diabetes
Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
The study is being conducted to evaluate and compare the pharmacokinetics of HRS-7535 tablets in subjects with moderate renal insufficiency and healthy subjects.
- Trial name
- NCT06132204
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
- Trial name
- NCT05411965
- Testing
- BR3003(T), BR3003B(R1), BR3003C(R2)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type II
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
- Trial name
- NCT02824874
- Testing
- Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Circadian Rhythm, Diabetes
Study of Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.
The investigators aimed to characterize human circadian clockwork in healthy individuals in comparison to obese and type 2 diabetic subjects, employing the noninvasive experimental approach allowing the study of circadian profile…
- Conditions
- Circadian Rhythm, Diabetes, Obesity
- Trial name
- NCT02384148
- Testing
- Circadian rhythm measurement, Skin biopsy
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Type 1 Diabetes, Type 2 Diabetes
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the safety and pancreas imaging properties of 18F-AV-133.
- Trial name
- NCT01515384
- Testing
- 18F-AV-133
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Healthy, Diabetes Mellitus, Type 2
A Study of LC542019 in Healthy Subjects and Subjects With T2DM
to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).
- Trial name
- NCT06333977
- Testing
- LC542019
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- LG Chem
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting…
- Trial name
- NCT06890286
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2
The Effects of LY2409021 on the Liver
This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days.
- Trial name
- NCT01588366
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects
The primary objective of this study is to determine the absolute bioavailability of SRT2104 as a 250 mg suspension, and to define the intravenous pharmacokinetics of SRT2104.
- Trial name
- NCT00937872
- Testing
- 250 mg SRT2104 Suspension, Carbon-14 radio-labeled SRT2104
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2881835 in Healthy People and People With Diabetes
This will be the first study in which LY2881835 is given to humans in order to evaluate the safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the body and its effect on blood sugar levels.
- Trial name
- NCT01358981
- Testing
- LY2881835
- Where
- Singapore
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
The purpose of this study is determine that Dapagliflozin has no effect on the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is coadministered with warfarin.
- Trial name
- NCT00904176
- Testing
- Dapagliflozin, Warfarin, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
T2DM (Type 2 Diabetes Mellitus)
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test…
- Trial name
- NCT07412015
- Testing
- treatment T (dose 1), treatment T (dose 2), treatment R (dose 1)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations
Background: Type 2 diabetes mellitus is a main risk factor for cardiovascular disease and heart failure, in part due to diabetic cardiomyopathy.
- Conditions
- Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Familiar Hypocalcuric Hypercalcemia, Healthy Volunteers
- Trial name
- RISC_7T (NCT02023489)
- Testing
- 1H/ 13C and 31P Magnetic Resonance Spectroscopy, Meal Tolerance Test, Hyperglycemic-hyperinsulinemic clamp
- Where
- Austria
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy Volunteers Type 2 Diabetes
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide.
- Trial name
- NCT04878406
- Testing
- NNC0480-0389, Semaglutide
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S